{"id":"W4389485847","doi":"10.1002/acn3.51946","title":"Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension","year":2023,"lang":"en","type":"article","venue":"Annals of Clinical and Translational Neurology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; University of Toronto; University Health Network; Ottawa Hospital; University of Ottawa","funders":"National Center for Advancing Translational Sciences; University of California, Irvine; Genentech; Grifols; Muscular Dystrophy Canada; Montreal Neurological Institute and Hospital; Horizon Therapeutics; National Institutes of Health; Argenx; CSL Behring; Eli Lilly and Company; University of Miami; Alnylam Pharmaceuticals; Union Chimique Belge; Alexion Pharmaceuticals; Biogen; Pfizer; Muscular Dystrophy Association; Momenta Pharmaceuticals; Sanofi; Myasthenia Gravis Foundation of America","keywords":"Myasthenia gravis; Medicine; Tolerability; Placebo; Adverse effect; Internal medicine; Pharmacodynamics; Antibody; Randomized controlled trial; Clinical trial; Clinical endpoint; Gastroenterology; Immunology; Pharmacokinetics; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002737584,0.001422586,0.002118622,0.0002784793,0.0002498706,0.00093392,0.0006712612,0.001462598,0.003667766],"category_scores_gemma":[0.001302409,0.0004246736,0.001645342,0.0002819322,0.0009509275,0.000843516,0.0003624342,0.002413977,0.000651975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004955161,"about_ca_system_score_gemma":0.0008280567,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004540626,"about_ca_topic_score_gemma":0.0008339273,"domain_scores_codex":[0.9993074,0.0003624394,0.00004273745,0.0001037792,0.00007450829,0.0001091678],"domain_scores_gemma":[0.998978,0.000260534,0.0002904349,0.0001011978,0.00007227174,0.0002975176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8626674,0.01993168,0.001940201,0.001894737,0.00128649,0.0002578361,0.000201105,0.001052911,0.02803759,0.000193217,0.001633402,0.08090346],"study_design_scores_gemma":[0.8059238,0.1881605,0.003333141,0.00005060599,0.0003191605,0.0001904599,0.0000221551,0.0002562634,0.0008716955,0.00006949079,0.0007893168,0.00001348463],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870989,0.007411831,0.0006771118,0.0005160057,0.0001669642,0.00237781,0.0006658282,0.00008802114,0.0009975582],"genre_scores_gemma":[0.9879539,0.003942226,0.001634337,0.00081666,0.0003399813,0.00244103,0.00132898,0.00002051337,0.001522313],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003667766,"threshold_uncertainty_score":0.01447791,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2996820793453627,"score_gpt":0.4817314937272266,"score_spread":0.1820494143818639,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}